C57BL/6JCya-Jak1em1/Cya
Common Name
Jak1-KO
Product ID
S-KO-18009
Backgroud
C57BL/6JCya
Strain ID
KOCMP-16451-Jak1-B6J-VA
When using this mouse strain in a publication, please cite “Jak1-KO Mouse (Catalog S-KO-18009) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Jak1-KO
Strain ID
KOCMP-16451-Jak1-B6J-VA
Gene Name
Product ID
S-KO-18009
Gene Alias
BAP004, C130039L05Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 4
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000102781
NCBI RefSeq
NM_146145
Target Region
Exon 3
Size of Effective Region
~1.0 kb
Overview of Gene Research
Jak1, short for Janus kinase 1, is a cytoplasmic tyrosine kinase. It is a key player in the JAK-STAT signaling pathway, which is involved in the transduction of cytokine-mediated signals. This pathway is crucial for many biological processes such as cell growth, differentiation, and immune response [1,2,3,4,5,6,7].
In inflammatory bowel disease (IBD), the JAK-STAT pathway has been extensively studied. Tofacitinib, a JAK1 inhibitor, is licensed for induction and maintenance of ulcerative colitis, and other JAK1 inhibitors are under investigation [1,4]. In colorectal cancer, METTL3 promotes cancer progression by activating the JAK1/STAT3 signaling pathway. METTL3 increases JAK1 translation and STAT3 transcription, leading to enhanced cancer cell proliferation and metastasis [2]. In renal cell carcinoma, EHBP1L1 binds and stabilizes JAK1, promoting immune evasion through the IFN-γ/JAK1/STAT1/PD-L1 signaling axis. Inhibiting EHBP1L1 can enhance the efficacy of immune checkpoint blockade [3]. JAK1 also promotes HDV replication, and FDA-approved JAK1-specific inhibitors show antiviral effects in vitro [6]. The JAK1/JAK2 inhibitor ruxolitinib can inhibit mediator release from human basophils and mast cells, indicating its potential in treating inflammatory disorders [7].
In conclusion, Jak1 is essential for the proper functioning of the JAK-STAT signaling pathway, influencing various biological processes. Research using models related to Jak1, such as through inhibitor studies, has revealed its significance in diseases like IBD, colorectal cancer, renal cell carcinoma, and HDV-related hepatitis, as well as its potential in treating inflammatory disorders. This understanding of Jak1 provides valuable insights into disease mechanisms and potential therapeutic strategies.
References：
1. Harris, Clare, Cummings, J R Fraser. . JAK1 inhibition and inflammatory bowel disease. In Rheumatology (Oxford, England), 60, ii45-ii51. doi:10.1093/rheumatology/keaa896. https://pubmed.ncbi.nlm.nih.gov/33950226/
2. Sun, Yuechao, Gong, Weipeng, Zhang, Song. 2023. METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling pathway. In Cell death & disease, 14, 765. doi:10.1038/s41419-023-06287-w. https://pubmed.ncbi.nlm.nih.gov/38001065/
3. Pan, Yihui, Shu, Guannan, Fu, Liangmin, Zhang, Jiaxing, Wei, Jinhuan. 2023. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10, e2206792. doi:10.1002/advs.202206792. https://pubmed.ncbi.nlm.nih.gov/36775874/
4. Nielsen, Ole Haagen, Boye, Theresa Louise, Gubatan, John, Jaquith, James B, LaCasse, Eric C. 2023. Selective JAK1 inhibitors for the treatment of inflammatory bowel disease. In Pharmacology & therapeutics, 245, 108402. doi:10.1016/j.pharmthera.2023.108402. https://pubmed.ncbi.nlm.nih.gov/37004800/
5. Kopelman, Hannah, Kontzias, Christina, Alihosseni, Christopher, Feldman, Steven R. 2023. JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations. In Expert opinion on drug metabolism & toxicology, 19, 537-542. doi:10.1080/17425255.2023.2256227. https://pubmed.ncbi.nlm.nih.gov/37695699/
6. Heuschkel, Margaux J, Bach, Charlotte, Meiss-Heydmann, Laura, Baumert, Thomas F, Verrier, Eloi R. 2023. JAK1 promotes HDV replication and is a potential target for antiviral therapy. In Journal of hepatology, 80, 220-231. doi:10.1016/j.jhep.2023.10.030. https://pubmed.ncbi.nlm.nih.gov/37925078/
7. Poto, Remo, Cristinziano, Leonardo, Criscuolo, Gjada, Loffredo, Stefania, Varricchi, Gilda. 2024. The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells. In Frontiers in immunology, 15, 1443704. doi:10.3389/fimmu.2024.1443704. https://pubmed.ncbi.nlm.nih.gov/39188724/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.